Twist Bioscience (TWST) Capital Expenditures (2017 - 2026)

Twist Bioscience has disclosed Capital Expenditures across 10 years of filings, most recently posting -$4.4 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 449.44% year-over-year to -$4.4 million; the TTM figure through Mar 2026 stood at $32.2 million (up 649.88% YoY), while the FY2025 annual figure was $28.0 million, up 451.69% from the prior year.
• Capital Expenditures fell to -$4.4 million in Q1 2026, from $10.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for TWST reached as high as $40.6 million in Q2 2022 and fell as low as -$24.6 million in Q3 2023.
• The 5-year median for Capital Expenditures is $2.1 million (2024), against an average of $7.6 million.
• Annual changes were most pronounced in 2025 — Capital Expenditures jumped 1376.48% — and 2026, when it plunged 449.44%.
• A 5-year view of Capital Expenditures shows it stood at $11.8 million in 2022, then slumped by 87.26% to $1.5 million in 2023, then soared by 41.83% to $2.1 million in 2024, then jumped by 366.95% to $10.0 million in 2025, then sank by 144.46% to -$4.4 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$4.4 million, $10.0 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.